Healthcare News Uncategorized

Leukemia Therapeutics Market to Grow at 5.1% CAGR by 2025 – Ambit Biosciences Corporation, Takeda Pharmaceutical Company Limited, Biogen, Bristol-Myers Squibb Company, Celgene Corporation and others

Press Release

There are several recent developments, product launches, joint ventures, merges and accusations by the key market players and brands who will dominate the Leukemia Therapeutics market and hence Pharmaceutical industry for the forecast years 2019 to 2025.

This report has all the company profiles for the top players and brands and along with that the report also contains a synopsis of market definition, classifications, applications and market trends, and the Leukemia Therapeutic market drivers and restrains that are derived from a well know method called SWOT analysis.

Market Analysis:

Leukemia Therapeutics Market accounted for USD 10.2 billion in 2017 and is projected to grow at a CAGR of 5.1% during the forecast period of 2018 to 2025. The upcoming market report contains data for historic years 2016, the base year of calculation is 2017 and the forecast period is 2019 to 2025.

Download Sample PDF Report

Key Players:

  • Ambit Biosciences Corporation
  • Takeda Pharmaceutical Company Limited
  • Biogen
  • Bristol-Myers Squibb Company
  • Celgene Corporation
  • Cephalon
  • Clavis Pharma ASA
  • Eisai
  • Erytech Pharma
  • Genmab A/S
  • Genzyme Corporation
  • GlaxoSmithKline
  • Novartis AG
  • Pfizer
  • Hoffmann-La Roche Ltd
  • Sunesis Pharmaceuticals
  • Talon Therapeutics
  • Anatomics Pty
  • Medical Vision Australia Holdings among others.


Major Market Drivers and Restraints:

  • Advent of latest technologies for leukemia
  • Increasing development for new drugs
  • Rising awareness among patients
  • High costing involved for the development of new therapeutics
  • Adverse events of treatment


The global leukemia therapeutics market is segmented based on

  • disease type
  • treatment
  • stages
  • geographical segments

Based on disease type, the global leukemia therapeutics market is segmented into

  • chronic lymphatic leukemia
  • acute lymphatic leukemia and others

On the basis of treatment, the global leukemia therapeutics market is segmented into

  • chemotherapy
  • radiation therapy
  • immunotherapy
  • surgery
  • targeted therapy
  • bone marrow transplant
  • biological therapy
  • stem cell therapy

On the basis of stages, the global leukemia therapeutics market is segmented into

  • acute lymphocytic leukemia
  • acute myeloid leukemia
  • chronic myelogenous leukemia

Based on geography, the global leukemia therapeutics market report covers data points for 28 countries across multiple geographies such as

  • North America
  • South America
  • Europe
  • Asia-Pacific
  • Middle East
  • Africa

Some of the major countries covered in this report are

  • US., Canada, Germany, France, U.K., Netherlands, Switzerland, Turkey, Russia, China, India, South Korea, Japan, Australia, Singapore, Saudi Arabia, South Africa, and Brazil among others.

Competitive Landscape:

The global leukemia therapeutics market is consolidated due to the presence of limited number of players concentrated in few countries. These major players have adopted various organic as well as inorganic growth strategies such as mergers & acquisitions, new product launches, expansions, agreements, joint ventures, partnerships, and others to strengthen their position in this market.

Speak To Author